Premium
Plasma quercetin response to 12‐weeks supplementation: a randomized community clinical trial
Author(s) -
Jin Fuxia,
Nieman David C,
Shanely R. Andrew,
Knab Amy M,
Austin Melanie D
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.331.8
Subject(s) - quercetin , placebo , medicine , body mass index , randomized controlled trial , analysis of variance , placebo group , endocrinology , zoology , biology , biochemistry , alternative medicine , pathology , antioxidant
The purpose of this study was to determine if plasma quercetin response in humans is related to gender, age, body mass index (BMI), and other demographic and lifestyle factors. Subjects (N=1,002, ages 18 to 85 years, 60% female and 40% male) were recruited from the community and randomized to one of three groups, with supplements administered using double blinded procedures: Q‐500 (500 mg/day), Q‐1000 (1000 mg/day), or placebo. Fasting blood samples were obtained pre‐ and post‐study, analyzed for plasma quercetin, and then compared between and within groups by gender, age group (<40, 40–59, and ≥60 years), BMI (<25, 25–29.9, and ≥30 kg/m 2 ), self‐reported physical fitness level and diet intake (food group servings). A subgroup of 170 subjects provided additional fasting blood samples after one and two months supplementation. Quercetin supplementation over 12 weeks caused a significant increase in overnight‐fasted plasma quercetin, with a net increase of 332±21.0 and 516±30.8 μg/L for Q‐500 and Q‐1000 compared to 53.6±6.4 μg/L for placebo (interaction effect, P<0.001). The increase in plasma quercetin was achieved within the first month and maintained for the rest of the study. The increase in plasma quercetin was highly variable within each quercetin supplementation group, but was unrelated to age, gender, BMI, fitness levels, or dietary intake. Supported by grants from Coca‐Cola and Quercegen Pharma.